Park Ha Biological Technology Co., Ltd.
Park Ha Biological Technology Co., Ltd. (PHH) Stock Overview
Explore Park Ha Biological Technology Co., Ltd.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
78.9M
P/E Ratio
167.53
EPS (TTM)
$0.02
ROE
0.38%
PHH Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Park Ha Biological Technology Co., Ltd. (PHH) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 93.15, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $63.33.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 167.53 and a market capitalization of 78.9M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Company Profile
Park Ha Biological Technology Co., Ltd., investment holding company, develops skincare products in the People's Republic of China. The company operates in two segments, Product Sales and Franchise Service. It offers various products, such as basic skin physical protection, exfoliation, and sebum film repair to surface microecological balance, and anti-aging under the Park Ha brand. It sells products to customers through directly operated retail stores, and franchisees. The company was founded in 2016 and is headquartered in Wuxi, the People's Republic of China. Park Ha Biological Technology Co., Ltd. operates as a subsidiary of Xiaoqiu Holding Ltd.
Xiaoqiu Zhang
17
901 & 901-2, Wuxi
2005